Eisai Co., Ltd. (4523) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Eisai Co., Ltd. (4523:JPX), powered by AI.

Current Price
¥3,829
P/E Ratio
23.4
Market Cap
1.1T
Sector
Healthcare
What is the Eisai Co., Ltd. stock price forecast?

Eisai Co., Ltd. is currently trading at ¥3,829. View real-time AI analysis on Alpha Lenz.

What is Eisai Co., Ltd. insider trading activity?

View the latest insider trading data for Eisai Co., Ltd. on Alpha Lenz.

What is Eisai Co., Ltd.'s P/E ratio?

Eisai Co., Ltd.'s P/E ratio is 23.4.

Eisai Co., Ltd.

JPX · 4523
¥3,829+79(+2.11%)Market closedJPX regular session 09:00–15:00 JST
Ask about Eisai Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Eisai Co., Ltd. trades at a P/E of 23.4 (fair value) with modest ROE of 5.4%.

Ask for details

Company Overview

Eisai Co., Ltd. is a prominent Japanese pharmaceutical company engaged in the research, development, manufacture, and marketing of healthcare products. Known for its significant contributions to drug discovery and development, Eisai primarily focuses on therapeutic areas such as oncology, neurology, and gastrointestinal diseases. The company is renowned for developing Aricept, a leading treatment for Alzheimer's disease, showcasing its expertise in neurology. Eisai's operations extend across multiple sectors in healthcare, with a strong emphasis on innovation and patient-centric solutions. Its business model integrates cutting-edge research with robust clinical development through global partnerships and collaborations. By leveraging biopharmaceutical advancements, Eisai aims to address unmet medical needs and improve patient outcomes internationally. In the financial markets, Eisai Co., Ltd. plays a crucial role as a major player in the pharmaceutical industry, contributing to advancements in medical research and treatment options. Its commitment to research excellence and strategic global expansion underscores its status as a leader in the healthcare sector, impacting both local and international markets with its future-focused therapeutic developments.

CEOMr. Haruo Naito
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees10,917

Company Statistics

FY 2025

Profile

¥1,085,662,725,007Market Cap
¥789,400,000,000Revenue
0.00Shares Out
10,917Employees

Margins

78.62%Gross
13.24%EBITDA
6.89%Operating
7.74%Pre-Tax
6.09%Net

Valuation

23.38P/E
1.29P/B
1.38EV/Sales
9.88EV/EBITDA
151.88P/FCF

Growth (CAGR)

1.44%Rev 3Yr
2.56%Rev 5Yr
0.39%Op Inc 3Yr
-15.40%Op Inc 5Yr
1.68%Net Inc 3Yr
-17.06%Net Inc 5Yr

Returns

3.46%ROA
5.41%ROE
4.65%ROIC

Financial Health

¥265,561,000,000Cash & Cash Equivalents
¥255,018,000,000Net Debt
60.12%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Eisai Co., Ltd. (ticker: 4523) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 10,917 employees. Market cap is $1.1T.

The current price is 3,829 with a P/E ratio of 23.38x and P/B of 1.29x.

ROE is 5.41% and operating margin is 6.89%. Annual revenue is $789.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Eisai Co., Ltd. (4523) Stock Forecast 2026 ¥3,829 — Price, Financials & Analyst Targets | Alpha Lenz